Physician profile
Kailey Davis
NPI 1609618610
$3,017.00
in general payments reported to CMS, 2019-2025
23 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $915 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.86 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $341.39 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $215.22 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.49 | 2024-2025 | Caplyta |
| Inspire Medical Systems, INC. | $167.26 | 2025 | Inspire |
| Abiomed | $149.10 | 2025 | |
| Lilly USA, LLC | $128.41 | 2024-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $124.98 | 2025 | Auvelity |
| Kyowa Kirin, INC. | $120.56 | 2025 | |
| Merck Sharp & Dohme LLC | $114.09 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $86.38 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Si-Bone, INC. | $84.72 | 2025 | |
| Shield Therapeutics INC | $83.24 | 2024-2025 | |
| Abbvie INC. | $72.93 | 2024-2025 | |
| Organon LLC | $64.88 | 2025 | Nexplanon |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.62 | 2024-2025 | Veozah |
| Viiv Healthcare Company | $31.37 | 2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.45 | 2025 | Jardiance |
| Philips North America LLC | $21.46 | 2024 | (Ck7) Extended Holter |
| Takeda Pharmaceuticals U.S.A., INC. | $21.30 | 2024 | Trintellix |
| Sumitomo Pharma America, INC. | $19.99 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.93 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $14.37 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kailey Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.